Here's Why Novartis (NVS) is a Strong Momentum Stock

Novartis (NVS) is highlighted as a strong momentum stock, holding a Zacks #2 (Buy) Rank and 'A' ratings for both its Momentum and overall VGM Style Scores. The pharmaceutical giant's shares have gained 3.3% over the past four weeks, supported by recent upward revisions to fiscal 2025 earnings estimates, which increased the Zacks Consensus Estimate by $0.12 to $8.81 per share, alongside a 7.1% average earnings surprise. This performance, coupled with its robust drug portfolio and dominant market position, suggests NVS warrants consideration by investors.

Analysis

Novartis (NVS) is exhibiting strong bullish signals, underscored by a Zacks #2 (Buy) rank and top-tier 'A' ratings for both its overall VGM (Value, Growth, Momentum) and specific Momentum style scores. This positive quantitative assessment is supported by fundamental drivers, including a robust drug portfolio with key growth assets like Kesimpta, Pluvicto, and Leqvio. The market has responded favorably, with NVS shares appreciating 3.3% over the last four weeks. This price momentum is reinforced by positive forward-looking analyst sentiment, evidenced by two upward earnings estimate revisions for fiscal 2025 within the past 60 days. These revisions have lifted the Zacks Consensus Estimate by $0.12 to $8.81 per share. Furthermore, the company's track record of consistently beating expectations, demonstrated by an average earnings surprise of 7.1%, lends credibility to the current positive outlook.

Key Decisions for Investors

• Given the 'A' momentum score and recent 3.3% share price increase, momentum-focused investors should consider NVS as it shows a clear upward trend supported by positive earnings estimate revisions.
• Investors should evaluate the growth trajectory of the company's key drugs, such as Kesimpta and Pluvicto, as they are identified as the primary catalysts for future performance.
• The combination of a #2 (Buy) rank, strong style scores, and upwardly revised earnings estimates suggests that investors with existing positions could consider holding or adding, while those seeking new exposure in the pharma sector may find this a compelling entry point.
• Monitor the fiscal 2025 consensus earnings estimate of $8.81 per share for any future revisions, as this metric is a critical component of the current bullish thesis presented in the analysis.